Company intelligence / Profile preview

Pelias

Jupiter, Florida, USA

Ownership: Private
Employees: ~5
Development stage: Other

Overview

Pelias Therapeutics is a clinical-stage biotechnology company focused on developing novel treatments for cardiovascular diseases, specifically targeting ischemia-reperfusion injury (IRI). The company's lead candidate, PTX-022, is a proprietary formulation designed to be administered during primary percutaneous coronary intervention (PCI) to reduce infarct size in patients suffering from acute myocardial infarction (AMI). By protecting heart tissue from the damage that occurs when blood flow is restored, Pelias aims to improve long-term outcomes for heart attack survivors. The company is currently advancing its lead program through Phase 2 clinical trials.

Therapeutic areas: Cardiovascular
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Pelias.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pelias.

Explore the full profile